NCT06842186View on ClinicalTrials.gov

A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity

PHASE1RecruitingINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Obesity and Overweight

Interventions

DRUG

WVE-007

Stereopure siRNA oligonucleotide

Trial Locations (1)

MD-2025

RECRUITING

ARENSIA Research Clinic, Chisinau

All Listed Sponsors

lead

Wave Life Sciences Ltd.

INDUSTRY